| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7638536 | AKARX INC | 2-Acylaminothiazole derivative or salt thereof |
May, 2025
(1 year, 9 days from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8765764 | AKARX INC | 2-acylaminothiazole derivative or salt thereof |
Jan, 2023
(1 year, 3 months ago) | |
| US8338429 | AKARX INC | 2-acylaminothiazole derivative or salt thereof |
Jun, 2023
(9 months ago) | |
Doptelet is owned by Akarx Inc.
Doptelet contains Avatrombopag Maleate.
Doptelet has a total of 3 drug patents out of which 2 drug patents have expired.
Expired drug patents of Doptelet are:
- US8765764
- US8338429
Doptelet was authorised for market use on 21 May, 2018.
Doptelet is available in tablet;oral dosage forms.
Doptelet can be used as treatment of thrombocytopenia in an adult patient with chronic liver disease who is scheduled to undergo a procedure, treatment of thrombocytopenia in an adult patient with chronic immune thrombocytopenia who has had an insufficient response to a previous treatment.
Drug patent challenges can be filed against Doptelet from 21 May, 2022.
The generics of Doptelet are possible to be released after 26 June, 2026.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-246) | Jun 26, 2026 |
| New Indication(I-802) | Jun 26, 2022 |
| New Chemical Entity Exclusivity(NCE) | May 21, 2023 |
Drugs and Companies using AVATROMBOPAG MALEATE ingredient
NCE-1 date: 21 May, 2022
Market Authorisation Date: 21 May, 2018
Treatment: Treatment of thrombocytopenia in an adult patient with chronic liver disease who is scheduled to undergo a procedure; Treatment of thrombocytopenia in an adult patient with chronic immune thrombocytop...
Dosage: TABLET;ORAL
DOPTELET family patents
